Diabetes Will Lead Medtronic's Near Term Earnings Growth

Medtronic (NYSE:MDT) recently posted its Q2 FY19 numbers, which were better than street estimates, led by a steady growth across its segments. The company also revised its revenue guidance upward, and expects strong growth in the Diabetes segment for the full year. We currently forecast low...